Invivyd
Logotype for Invivyd Inc

Invivyd (IVVD) investor relations material

Invivyd Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Invivyd Inc
Q3 2026 earnings summary16 Nov, 2026

Executive summary

  • PEMGARDA Q3 revenue was $15.449M, up 18% from $13.129M, while net loss widened to $33.468M from $10.470M as R&D and SG&A increased.

  • Cash and cash equivalents were $126.398M at September 30, 2026; without future external financing, available cash is not expected to fund operations and capital needs beyond one year, raising substantial doubt about going concern.

  • VYD2311 advanced in Phase 3 and Phase 2 programs; DECLARATION interim data and a regulatory update were expected in Q4 2026 following FDA dialogue on the accelerated approval approach.

Financial highlights

  • Q3 product revenue was $15.449M vs. $13.129M YoY; nine-month revenue was $43.478M vs. $36.219M, driven by higher PEMGARDA demand.

  • Q3 R&D expense rose to $18.7M from $8.0M and SG&A to $30.3M from $15.0M, primarily reflecting increased clinical and commercial activity.

  • Q3 operating loss was $34.679M vs. $11.023M; nine-month operating loss was $123.635M vs. $43.005M.

  • Nine-month operating expenses rose to $167.113M from $79.224M, led by R&D of $78.834M and SG&A of $84.931M.

  • Nine-month net loss was $119.261M vs. $41.419M; Q3 and nine-month loss per share were $0.10 vs. $0.06 and $0.38 vs. $0.30, respectively.

Outlook and guidance

  • DECLARATION interim analyses of antibody titers, pharmacokinetics, immunogenicity and safety were planned for Q4 2026; positive results could support a BLA under the accelerated approval pathway, with clinical events continuing as confirmatory data.

  • Initial FLINTLOCK data are expected in mid-2027; the Phase 2 trial evaluates high-dose VYD2311 in Long COVID or Post-Vaccination Syndrome.

  • VMS063 was expected to reach IND readiness in H2 2026, with clinical development anticipated in 2027; production scale-up is underway.

  • PEMGARDA’s EUA is set to terminate June 29, 2027; FDA discussions on next steps continue.

  • Expenses are expected to rise with clinical development, manufacturing and commercialization; funding may come from revenue, equity, grants, debt or partnerships.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Invivyd earnings date

Logotype for Invivyd Inc
Q4 202618 Mar, 2027
Invivyd
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Invivyd earnings date

Logotype for Invivyd Inc
Q4 202618 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Invivyd Inc., a clinical-stage biopharmaceutical company, is focused to the discovery, development, and commercialization of antibody-based solutions targeting infectious diseases, with a primary focus on the United States. The company's mission centers on delivering antibody-based therapies to protect vulnerable populations against circulating viral threats, such as SARS-CoV-2, leveraging advanced antibody engineering and viral surveillance techniques. Invivyd's lead product candidate, adintrevimab, is a neutralizing antibody undergoing clinical trials for both treatment and prevention of coronavirus disease. Additionally, the company is developing monoclonal antibody candidates, including VYD222 and VYD224, aimed at offering neutralizing protection against SARS-CoV-2, alongside discovery stage candidates for seasonal influenza prevention. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the Nasdaq.